explore -WSS

explore

author：hotspot 2025-09-29 21:26:17 - browse：12852

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Novo Nordisk testing Wegovy against alcohol

Wikipedia

WSS

Leukemia patients are helped by Syndax's new type of therapy

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Spinal cord stimulation reduces pain in amputees, study finds

ALS treatment from Biogen, Ionis fails in study

Teach medical students about patients with intellectual disabilities

Why sickle cell disease is getting the first CRISPR treatment

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Virginia high school admissions case could be legal follow

Roche to buy Carmot Therapeutics, developer of obesity drugs

Psychedelics group wrestles with new pharma identity

What causes an itch? Researchers may have solved the mystery

What does generative AI mean for health care? We asked experts

As H5N1 spreads in cows, experts warn against drinking raw milk

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Free medical tuition alone isn't enough to close gaps in primary care

Virginia high school admissions case could be legal follow

The United States must get value

leisure time

Novo Nordisk testing Wegovy against alcohol

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Fertility clinic egg and embryo storage is a disaster

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

SCOTUS to consider access to abortion pill mifepristone

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

leisure time

hotspot

Wikipedia

hotspot